Groundbreaking Artificial Human Platelet Lysate Revolutionizes Cell Culture
PL BioScience GmbH, headquartered in Aachen, Germany, is making waves in the world of biotechnology with its revolutionary development—the first-ever artificial Human Platelet Lysate (HPL). In collaboration with the Korean biotech leader, DewCell Biotherapeutics, PL BioScience has harnessed innovative technology to transform lab-grown platelets into a highly effective cell culture supplement. According to GlobeNewswire, this groundbreaking advancement promises to reshape the landscape of regenerative medicine and cell therapy.
A New Era in Cell Culture Technology
The creation of artificial HPL marks a significant leap in cell culture technology. This fully lab-made, scalable product emerges as a superior alternative to animal-derived supplements like Fetal Calf/Bovine Serum (FCS/FBS). Unlike its natural counterpart—derived from donated human blood platelets—artificial HPL offers abundant supply, enhancing both safety and performance in cell cultures. It aligns with global ethical demands for animal-free laboratory practices, setting a new industry standard.
The Powerhouse Partnership: PL BioScience and DewCell
This potent collaboration between PL BioScience and DewCell Biotherapeutics is a testament to the synergy between innovation and expertise. DewCell’s remarkable ability to generate artificial platelets from stem cells complements PL BioScience’s proprietary method for HPL production. The outcome is an exceptional cell culture supplement capable of advancing modern medicine and biopharmaceutical applications without the limitations of natural platelet sources.
Safety, Sustainability, and Performance
Artificial HPL offers unmatched safety and sustainability, being free from animal-derived pathogens and utilizing outdated human blood platelets that would otherwise go to waste. Its high-performance capabilities make it a pivotal tool for advancing cell therapy, stem cell research, and regenerative medicine. The new technology ensures consistent and robust cell proliferation, addressing the industry’s growing need for scalable, ethical solutions.
A Step Towards Global Impact
Dr. Hatim Hemeda, CEO of PL BioScience, emphasizes the impact of this innovation, stating, “This scalable artificial HPL solution can be produced in nearly unlimited supply, meeting the growing demands of the biopharmaceutical industry.” The company’s ELAREM™ line of xeno-free HPL products represents a significant stride toward accessible and ethical regenerative medicine, offering seamless translation from research to patient treatment.
A Promising Future for Cell-based Pharmaceuticals
Human Platelet Lysate (HPL) plays a critical role in supporting cell growth and expansion, particularly in biopharmaceutical manufacturing. Compared to traditional cell culture supplements, HPL delivers superior, consistent results, ushering in a new era for cell-based therapies. PL BioScience’s breakthrough further solidifies its leadership in developing next-generation solutions for complex biological research and clinical development.
For more information on PL BioScience and the ELAREM™ product innovations, please visit their official website.
